肺部疾病治療市場（按產品類型、給藥途徑、分銷管道、適應症和最終用戶分類）—2025-2032 年全球預測

預計到 2032 年，肺部疾病藥物市場將成長至 1,613.7 億美元，複合年成長率為 8.16%。

主要市場統計數據
基準年2024年	861.4億美元
預計2025年	932.5億美元
預測年份：2032年	1613.7億美元
複合年成長率（%）	8.16%

不斷變化的患者需求、監管複雜性以及臨床和商業性需求的融合為肺部藥物創新奠定了基礎

肺部疾病治療領域正處於曲折點，科學突破與不斷變化的患者期​​望和不斷演變的監管要求交織在一起。過去十年，生物製藥的進步重塑了從氣喘到肺動脈高壓等疾病的臨床治療路徑。隨著醫療保健服務日益轉向門診和居家環境，治療效果與以患者為中心的設計之間的相互作用已成為臨床應用的決定性因素。這些因素迫使相關人員重新評估藥物研發、臨床開發和商業化過程中的優先事項。

本執行摘要概述了影響相關人員如何思考藥物設計、給藥途徑和分銷策略的關鍵發展。本執行摘要並非關注簡單的交易指標，而是關注病患療效、營運韌性和付款方接受度。透過將治療方法選擇置於醫療保健系統壓力和患者偏好的更廣泛背景下，本摘要為後續的深入分析組裝了實用基準。其目標是為領導者提供簡潔的、實證的觀點，以指南近期決策，同時為未來的創新保留策略選擇。

顛覆性的科學進步、數位療法和基於價值的護理模式如何重塑肺部護理中的藥物開發、交付和病人參與

多項變革性變革正在重新定義肺部疾病藥物的發現、核准和病患給藥方式。生物學方法和標靶小分子正在將治療套件擴展到傳統支氣管擴張劑和吸入性皮質類固醇之外，從而能夠針對重症氣喘和間質性肺病等不同適應症制定個人化治療方案。同時，設備創新，尤其是乾粉吸入器、定量吸入器和霧化器系統的改進，正在彌合藥理學與有效給藥之間的差距。這些技術進步因數位健康能力的日益整合而進一步放大，從依從性監測到遠端醫療支援的治療方案滴定。

同時，基於價值的合約以及對長期臨床療效的關注正在改變付款方和提供者的行為。製造商正在透過風險分擔安排、療效研究和更複雜的健康經濟證據包來應對。供應鏈韌性和在岸生產考量也成為焦點，影響製劑配方、包裝和給藥途徑的決策。這些轉變要求公司在研發、監管、生產和商業團隊之間採取跨職能的方法，以病人為中心的證據和可衡量的臨床效果為基礎。

評估 2025 年美國關稅對藥品採購、製造決策和跨境臨床營運的累積經濟和供應鏈影響

到2025年，美國關稅政策變化的累積效應將為肺部疾病藥物製造商、合約開發商和經銷商帶來新的營運複雜性。關稅帶來的成本壓力正在影響活性藥物原料藥的採購、製造外包的選擇、二次包裝的位置等等。因此，籌資策略現在通常會權衡關稅的影響與專業化製造能力和關鍵地區監管協調帶來的好處。這些動態也會波及下游，影響庫存計畫、吸入藥物和預填充式注射器的前置作業時間，以及關於冗餘供應商網路的決策。

為了應對這種情況，一些製造商正在多元化其供應商基礎，並加強確保高度依賴的組件（例如專用吸入器致動器和生物製藥）的短期庫存緩衝。由於全球供應商的合規性和關稅風險狀況都需要評估，監管提交和品質監督也變得越來越複雜。這種環境也加速了關於設備組裝和無菌填充等關鍵步驟垂直整合的討論，因為企業正在努力降低其受突然政策變化影響的風險。簡而言之，關稅變化正在將供應鏈策略從成本控制問題提升為臨床專案可行性和商業性化準備的核心要素。

從細分角度觀點介紹影響肺部藥物成功採用和臨床結果的產品、給藥途徑、分銷、適應症和最終用戶動態

細緻的細分分析揭示了臨床需求、給藥技術和通路動態在哪些方面相互交織，最終決定了產品的優先順序。考慮到產品類型（生物製藥、支氣管擴張劑、聯合治療和吸入性皮質類固醇）的細分，可以清楚地看出，每個類別對臨床開發和設備相容性都有不同的要求。吸入性皮質類固醇本身又進一步細分為倍氯米松、Budesonide和Fluticasone替卡松，每種藥物都有各自的配方穩定性和設備性能影響，從而影響處方者的偏好和依從性。

乾粉吸入器、定量吸入器和霧化器等吸入方式需要配方科學家和設備工程師密切合作，以最佳化藥物沉積並提升患者便利性。預填充式注射器和管瓶注射劑需要考慮低溫運輸和無菌性，而膠囊、溶液和片劑等口服劑型雖然具有規模化生產優勢，但在依從性和藥物動力學方面卻存在差異。線下和線上藥局的分銷管道差異化改變了藥物的取得方式，需要不同的商業策略才能觸達醫生和病人。

以適應症為基礎的細分凸顯了氣喘、慢性阻塞性肺病、囊腫纖維化、間質性肺病、肺纖維化、肺動脈高壓和呼吸道感染疾病等疾病治療的複雜性。每個臨床領域都優先考慮不同的終點、安全性和病患教育需求。最後，終端使用者細分市場涵蓋門診護理中心、居家照護機構、醫院和專科診所，凸顯了服務模式和培訓對於最佳治療效果的重要性。這些相互交叉的細分市場需要製定全面的產品策略，將製劑配方、設備設計和分銷與臨床路徑和治療環境結合。

美洲、歐洲、中東和非洲地區以及亞太地區的區域動態影響著肺部藥物研究的重點、監管途徑、定價談判和病患獲取

區域背景決定了肺部治療的臨床開發重點、監管策略和商業性方法。在美洲，付款人和醫療保健提供者越來越關注現實世界的結果和成本效益，這促使製造商提供強力的核准後證據並參與創新合約。北美監管路徑強調數據透明度和患者報告的結果，這反過來又影響了研究設計和說明書的預期。

歐洲、中東和非洲的報銷框架和衛生技術評估方法多種多樣，需要製定針對特定地區的衛生經濟模型和靈活的定價策略。不同地區的監管時間表和器械核准細節差異巨大，影響生物製藥和器械製造商的上市階段。在亞太地區，新治療方法的快速推出與多樣化的法律規範和製造生態系統並存，從而促進了本地合作。該地區的相關人員通常優先考慮可及性、供應本地化和可擴展製造，這可以加速器械整合學名藥競爭。在各個地區，區域研發中心和卓越中心正在成為進行臨床試驗和上市後監測的關鍵地點，這推動了製定個人化策略的需求，這些策略需要考慮到監管的特殊性、付款方的期望和患者的可及性途徑。

肺癌治療生態系統中領先的生物製藥和設備參與者的策略競爭行為、合作模式和創新組合

肺部治療生態系的競爭態勢由差異化的產品組合、設備能力和夥伴關係策略決定。主要企業正在將治療創新與設備專業知識相結合，打造旨在提高依從性和治療效果的整合解決方案。其他公司則專注於特定適應症，尋求互補的策略，透過有針對性的臨床試驗和患者援助計畫建立臨床差異化。生物製藥開發商和醫療設備製造商之間的策略聯盟已變得司空見慣，從而加快了產品的應用速度，並增強了對真實世界療效的認知。

創新領導力也仰賴卓越的供應鏈和製造能力。投資於先進的無菌填充、可擴展的吸入裝置組裝以及強大的品質系統的公司，能夠更好地滿足監管審查，並在需求激增期間保持供應的連續性。商業性，與付款人和關鍵意見領袖建立密切關係，並透過可操作的臨床研究證明其價值的公司往往能夠獲得更有利的處方地位。最後，擁有敏捷研發能力且在特定臨床領域表現卓越的中型市場和新興企業，往往會成為尋求擴展其生技藥品和器械相關產品的大型公司的理想合作夥伴，這凸顯了併購和許可作為產品組合更新持續驅動力的作用。

產業領導者應採取優先策略行動，加速創新，確保供應鏈的彈性，並最佳化其肺癌藥物組合的商業模式

行業領導者應採取一系列優先行動，將科學創新與商業性可行性和營運韌性相結合。首先，在研發生命週期的早期階段整合設備和配方開發，同時而非依序考慮吸入性能、病人易用性和監管證據。早期合作可以降低後期重新設計的風險，並提高產品在上市時獲得良好採用的可能性。

其次，要實現關鍵零件供應商網路多元化，並考慮選擇性地將高風險製造流程近岸外包，以降低關稅和地緣政治風險。此外，還應對專用致動器、預填充式注射器和生物製藥採用基於情境的庫存計劃和雙重籌資策略。第三，投資於針對重症氣喘和肺動脈高壓等高負擔適應症的現實世界證據和基於結果的契約，以證明其對付款人的長期價值。第四，制定差異化的通路策略，滿足線上和線下藥局的不同需求，同時確保在所有通路提供一致的病患支援和教育。最後，與專科診所和居家照護提供者建立夥伴關係，以促進其在門診和家庭環境中的應用，並獲得有助於迭代產品改進和上市後安全監測的見解。

結合臨床證據綜合、相關人員訪談和供應鏈分析的強大混合方法可確保獲得可操作且有效的見解

本執行摘要所依據的研究採用了穩健的混合方法，旨在提供基於證據的可操作見解。臨床證據綜合運用了同儕審查文獻、現行指引和註冊數據，以繪製治療前景圖譜，並比較與關鍵適應症相關的終點指標。此外，我們還與價值鏈上的相關人員（研究人員、配方師、臨床實驗專家和患者權益倡導者）進行了訪談和結構化討論，以提供深入的定性研究，並將定量訊號和操作挑戰具體化。

供應鏈分析繪製了關鍵供應商圖譜，評估了關稅對採購決策的影響，並評估了吸入裝置、無菌注射劑和口服固體製劑的生產方案。商業評估整合了線下和線上藥局的通路動態，並考慮了病患在門診護理中心、居家照護機構、醫院和專科診所的就醫障礙。透過對調查方法和資料來源進行三角檢驗，並由獨立專家驗證關鍵調查方法，檢驗了方法的嚴謹性，為決策提供了切實可行的見解。

整合相關人員的策略要務，將科學進步轉化為可及的、具成本效益的、以病人為中心的肺部疾病藥物

總而言之，科學、設備工程、付款人期望和供應鏈現實等諸多因素的匯聚正在再形成肺部治療領域的格局。積極整合設備和製劑開發、制定彈性籌資策略並產生令人信服的真實世界證據的利益相關人員，將最有能力將創新轉化為持續的臨床和商業性成功。專注於產品類型（生物製藥、支氣管擴張劑、聯合治療和吸入性皮質類固醇，包括倍氯米松、Budesonide和Fluticasone等亞型）的細分，將確保治療設計符合真實世界用例和患者需求。

同樣，謹慎選擇給藥途徑——乾粉吸入器、定量吸入器或霧化器；透過預填充式注射器或管瓶注射；或透過膠囊、液體或片劑口服——將決定下游的生產、監管和分銷影響。透過將這些維度與美洲、中東和非洲以及亞太地區的區域實際情況相結合，並瞄準從門診護理中心到居家照護機構再到專科診所的終端用戶，組織可以製定有韌性的策略，以改善患者治療效果和業務績效。一種以證據主導的、在創新與務實的商業化之間取得平衡的綜合方法將引領未來發展方向。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 將數位吸入器感測器與即時藥物依從性監測和分析相結合
• 針對第 2 型發炎的長效生物療法在重症氣喘治療中的出現
• 慢性阻塞性肺病 (COPD) 患者擴大採用結合 ICS、LABA 和 LAMA 的三重吸入器
• 開發吸入式基因編輯方法用於標靶治療肺部疾病
• 擴大吸入式抗呼吸道融合病毒（RSV）抗體在兒科病患的臨床試驗
• 新冠疫情後，對基於 mRNA 的呼吸道疫苗和療法的投資增加

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 肺病藥物市場（依產品類型）

• 生物製藥
• 支氣管擴張劑
• 聯合治療
• 吸入性皮質類固醇
  • 倍氯米松
  • Budesonide
  • Fluticasone

9. 肺部疾病藥物市場（依給藥途徑）

• 吸入
  • 乾粉吸入器
  • 定量噴霧吸入器
  • 噴霧器
• 注射
  • 預填充式注射器
  • 管瓶
• 口服
  • 膠囊
  • 液體
  • 藥片

第 10 章 肺病藥物市場（依通路）

• 線下藥局
• 網路藥局

第11章 肺部疾病藥物市場（按適應症）

• 氣喘
• 慢性阻塞性肺病（COPD）
• 囊腫纖維化
• 間質性肺部疾病
• 肺纖維化
• 肺動脈高壓
• 呼吸道感染疾病

第12章 肺部疾病藥物市場（依最終使用者）

• 門診治療中心
• 居家照護環境
• 醫院
• 專科診所

第13章肺病藥物市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 肺部疾病藥物市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 各國肺病藥物市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Sanofi SA
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Johnson & Johnson
  • Chiesi Farmaceutici SpA

The Pulmonary Drugs Market is projected to grow by USD 161.37 billion at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 86.14 billion
Estimated Year [2025]	USD 93.25 billion
Forecast Year [2032]	USD 161.37 billion
CAGR (%)	8.16%

Setting the stage for pulmonary therapeutics innovation with evolving patient needs, regulatory complexity, and converging clinical and commercial imperatives

The pulmonary therapeutic landscape stands at an inflection point where scientific breakthroughs converge with changing patient expectations and evolving regulatory demands. Over the past decade, advances in biologics, device engineering, and real-world data analytics have reshaped clinical pathways for conditions ranging from asthma to pulmonary hypertension. As care delivery increasingly shifts toward ambulatory and home settings, the interplay between therapy performance and patient-centric design has become a decisive factor in clinical adoption. These forces collectively require stakeholders to reassess priorities across discovery, clinical development, and commercialization.

This executive summary synthesizes critical developments that influence how stakeholders should think about drug design, route of administration, and distribution strategy. It frames the conversation around patient outcomes, operational resilience, and payer acceptance rather than simple transactional metrics. By situating therapeutic choices within the broader context of health system pressures and patient preferences, the introduction sets a pragmatic baseline for the deeper analyses that follow. The aim is to provide leaders with a concise, evidence-oriented perspective to guide near-term decisions while keeping strategic optionality for future innovation.

How disruptive scientific advances, digital therapeutics, and value-based care models are reshaping drug development, delivery, and patient engagement in pulmonary medicine

Several transformative shifts are redefining how pulmonary drugs are discovered, approved, and delivered to patients. Biologic modalities and targeted small molecules are expanding the therapeutic toolkit beyond traditional bronchodilators and inhaled corticosteroids, enabling personalized approaches for heterogeneous indications such as severe asthma and interstitial lung disease. At the same time, device innovation-particularly improvements in dry powder inhalers, metered dose inhalers, and nebulizer systems-is closing the gap between pharmacology and effective real-world delivery. These technological advances are being amplified by stronger integration of digital health capabilities, from adherence monitoring to telemedicine-enabled titration of therapy.

Concurrently, value-based contracting and greater emphasis on long-term clinical outcomes are changing payer and provider behavior. Manufacturers are responding with risk-sharing arrangements, outcomes studies, and more sophisticated health economic evidence packages. Supply chain resilience and onshore manufacturing considerations are also taking center stage, influencing decisions about formulation, packaging, and route-of-administration choices. Together, these shifts demand that companies adopt cross-functional approaches that align R&D, regulatory affairs, manufacturing, and commercial teams around patient-centric evidence and measurable clinical impact.

Assessing the cumulative economic and supply chain consequences of United States tariffs in 2025 on drug sourcing, manufacturing decisions, and cross-border clinical operations

The cumulative effect of tariff policy changes in the United States through 2025 has introduced a new layer of operational complexity for manufacturers, contract developers, and distributors serving pulmonary therapeutics. Tariff-driven cost pressures have influenced where companies source active pharmaceutical ingredients, select contract manufacturing organizations, and locate secondary packaging operations. As a result, procurement strategies now often weigh tariff exposure against the benefits of specialized capacity and regulatory alignment in key geographies. These dynamics reverberate downstream, affecting inventory planning, lead times for inhalers and prefilled syringes, and decisions about redundant supplier networks.

In response, several manufacturers have intensified efforts to diversify supplier bases and to secure near-term inventory buffers for high-dependency components such as specialized inhaler actuators and biologic drug substance. Regulatory submissions and quality oversight have become more complex as global suppliers are evaluated against both compliance and tariff risk profiles. This environment also accelerates conversations about vertical integration for critical steps like device assembly or sterile fill-finish, as organizations seek to reduce exposure to sudden policy shifts. In short, tariff changes have elevated supply chain strategy from a cost-management issue to a core component of clinical program viability and commercial readiness.

Segment-level perspectives that reveal product, administration route, distribution, indication, and end-user dynamics driving differential adoption and clinical outcomes in pulmonary drugs

A nuanced segmentation analysis reveals where clinical need, delivery technology, and channel dynamics intersect to shape product priorities. When considering product type segmentation across biologics, bronchodilators, combination therapies, and inhaled corticosteroids, it is clear that each category imposes distinct requirements for clinical development and device compatibility. Inhaled corticosteroids themselves break down further into beclomethasone, budesonide, and fluticasone variants, each with unique formulation stability and device performance implications that influence prescriber preference and adherence.

Route of administration further differentiates strategy: inhalation modalities including dry powder inhalers, metered dose inhalers, and nebulizers demand close collaboration between formulation scientists and device engineers to optimize deposition and patient usability. Injection options such as prefilled syringes and vials carry their own cold-chain and sterility considerations, while oral forms in capsules, liquids, and tablets present manufacturing scale advantages but different adherence and pharmacokinetic profiles. Distribution channels, split between offline pharmacies and online pharmacies, alter access dynamics and require distinct commercial tactics to reach physicians and patients.

Indication-based segmentation highlights therapeutic complexity across asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and respiratory infections; each clinical area prioritizes different endpoints, safety profiles, and patient education needs. Finally, end-user segmentation encompassing ambulatory care centers, homecare settings, hospitals, and specialty clinics underscores the importance of service models and training to achieve optimal therapeutic outcomes. Together, these intersecting segmentations call for integrated product strategies that align formulation, device design, and distribution with clinical pathways and care settings.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape research priorities, regulatory pathways, pricing negotiations, and patient access for pulmonary therapies

Geographic context shapes clinical development priorities, regulatory strategy, and commercial approaches in pulmonary therapeutics. In the Americas, payers and providers are increasingly focused on real-world outcomes and cost-effectiveness, pushing manufacturers to produce robust post-approval evidence and to engage in innovative contracting. North American regulatory pathways emphasize data transparency and patient-reported outcomes, which in turn affect trial design and labeling expectations.

Europe, Middle East & Africa presents a mosaic of reimbursement frameworks and health technology assessment approaches that require localized health economic models and adaptable pricing strategies. Regulatory timelines and device approval nuances differ substantially across the region, influencing where biopharma and device firms stage their launches. In Asia-Pacific, rapid adoption of novel therapeutic approaches coexists with diverse regulatory structures and manufacturing ecosystems that favor local partnerships. Stakeholders in this region often prioritize access, localization of supply, and scalable manufacturing, which can accelerate the deployment of device-integrated therapies and generic competition. Across all regions, regional R&D hubs and centers of excellence are emerging as critical nodes for clinical trial execution and post-market surveillance, reinforcing the need for geographically tailored strategies that consider regulatory idiosyncrasies, payer expectations, and patient access pathways.

Strategic competitive behaviors, partnership models, and innovation portfolios that distinguish leading biopharma and device players in the pulmonary drugs ecosystem

Competitive dynamics in the pulmonary drugs ecosystem are defined by differentiated portfolios, device capabilities, and partnership strategies. Leading companies combine therapeutic innovation with device expertise to create integrated solutions that improve adherence and therapeutic outcomes. Others pursue a complementary playbook by focusing on specialty indications where clinical differentiation can be established through targeted trials and curated patient support programs. Strategic alliances between biopharma developers and device manufacturers have become common, enabling faster time-to-use and stronger claims around real-world performance.

Innovation leadership is also contingent on supply chain and manufacturing excellence. Firms that invest in advanced sterile fill-finish, scalable inhalation device assembly, and robust quality systems are better positioned to respond to regulatory scrutiny and to maintain supply continuity during demand spikes. Commercially, companies that cultivate close relationships with payers and key opinion leaders and that support value demonstration through pragmatic clinical studies tend to secure more favorable formulary positioning. Finally, mid-sized and emerging players that excel in nimble R&D and specific clinical niches frequently become attractive partners for larger organizations seeking to expand biologics or device-enabled offerings, underscoring the role of M&A and licensing as ongoing drivers of portfolio renewal.

Priority strategic actions for industry leaders to accelerate innovation, secure resilient supply chains, and optimize commercial models for pulmonary drug portfolios

Industry leaders should pursue a set of prioritized actions that align scientific innovation with commercial viability and operational resilience. First, integrate device and formulation development earlier in the R&D lifecycle to ensure that inhalation performance, patient usability, and regulatory evidence are considered in parallel rather than sequentially. Early alignment reduces late-stage redesign risk and improves the chance of favorable adoption at launch.

Second, diversify supplier networks for critical components and consider selective nearshoring of high-risk manufacturing steps to mitigate tariff and geopolitical exposure. This should be complemented by scenario-driven inventory planning and dual-sourcing strategies for specialized actuators, prefilled syringes, and biologic drug substance. Third, invest in real-world evidence generation and outcomes-based contracts tailored to high-burden indications such as severe asthma and pulmonary hypertension to demonstrate long-term value to payers. Fourth, develop differentiated channel strategies that address the distinct requirements of offline and online pharmacies while ensuring consistent patient support and education across settings. Finally, cultivate partnerships with specialty clinics and homecare providers to accelerate adoption in ambulatory and home settings, and to capture insights that can inform iterative product improvements and post-market safety monitoring.

Robust mixed-methods approach combining clinical evidence synthesis, stakeholder interviews, and supply chain analysis to ensure actionable and validated insights

The research underpinning this executive summary employed a robust mixed-methods approach to ensure findings are evidence-based and actionable. Clinical evidence synthesis drew on peer-reviewed literature, guideline updates, and registries to map therapeutic landscapes and to compare endpoints relevant to key indications. In parallel, interviews and structured discussions with stakeholders across the value chain-clinical investigators, formulary decision-makers, manufacturing experts, and patient advocates-provided qualitative depth that contextualized quantitative signals and operational challenges.

Supply chain analysis included mapping of critical suppliers, assessment of tariff impacts on sourcing decisions, and evaluation of manufacturing options for inhalation devices, sterile injectables, and oral-solid dosage forms. Commercial assessments integrated channel dynamics for offline and online pharmacies and considered patient access barriers across ambulatory care centers, homecare settings, hospitals, and specialty clinics. Throughout the study, methodological rigor was maintained through triangulation of data sources and validation of key findings with independent subject-matter experts, yielding insights that are both practical and defensible for decision-making.

Synthesis of strategic imperatives for stakeholders to translate scientific advances into accessible, cost-effective, and patient-centered pulmonary therapies

In conclusion, the pulmonary drugs landscape is being reshaped by converging forces in science, device engineering, payer expectations, and supply chain realities. Stakeholders who proactively integrate device and formulation development, build resilient sourcing strategies, and generate compelling real-world evidence will be best positioned to translate innovation into sustained clinical and commercial success. Attention to segmentation-across product types such as biologics, bronchodilators, combination therapies, and inhaled corticosteroids with subtypes including beclomethasone, budesonide, and fluticasone-ensures that therapeutic design aligns with real-world use cases and patient needs.

Similarly, deliberate choices about route of administration, whether inhalation via dry powder inhalers, metered dose inhalers, and nebulizers, injection via prefilled syringes and vials, or oral formats in capsules, liquids, and tablets, determine downstream manufacturing, regulatory, and distribution implications. By synthesizing these dimensions with regional realities across the Americas, Europe Middle East & Africa, and Asia-Pacific and by targeting end users from ambulatory care centers to homecare settings and specialty clinics, organizations can craft resilient strategies that improve patient outcomes and operational performance. The path forward favors integrated, evidence-driven approaches that balance innovation with pragmatic commercialization.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of digital inhaler sensors with real time adherence monitoring and analytics
• 5.2. Emergence of long acting biologic therapies targeting Type 2 inflammation in severe asthma management
• 5.3. Growing adoption of triple combination inhalers delivering ICS LABA and LAMA for COPD patients
• 5.4. Development of inhaled gene editing approaches for targeted pulmonary disease treatment
• 5.5. Expansion of clinical trials for inhaled monoclonal antibodies against RSV in pediatric patients
• 5.6. Rising investment in mRNA based respiratory vaccines and therapeutics beyond COVID 19

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Drugs Market, by Product Type

• 8.1. Biologics
• 8.2. Bronchodilators
• 8.3. Combination Therapies
• 8.4. Inhaled Corticosteroids
  • 8.4.1. Beclomethasone
  • 8.4.2. Budesonide
  • 8.4.3. Fluticasone

9. Pulmonary Drugs Market, by Route Of Administration

• 9.1. Inhalation
  • 9.1.1. Dry Powder Inhalers
  • 9.1.2. Metered Dose Inhalers
  • 9.1.3. Nebulizers
• 9.2. Injection
  • 9.2.1. Prefilled Syringes
  • 9.2.2. Vials
• 9.3. Oral
  • 9.3.1. Capsules
  • 9.3.2. Liquids
  • 9.3.3. Tablets

10. Pulmonary Drugs Market, by Distribution Channel

• 10.1. Offline Pharmacies
• 10.2. Online Pharmacies

11. Pulmonary Drugs Market, by Indication

• 11.1. Asthma
• 11.2. Chronic Obstructive Pulmonary Disease (COPD)
• 11.3. Cystic Fibrosis
• 11.4. Interstitial Lung Disease
• 11.5. Pulmonary Fibrosis
• 11.6. Pulmonary Hypertension
• 11.7. Respiratory Infections

12. Pulmonary Drugs Market, by End User

• 12.1. Ambulatory Care Centers
• 12.2. Homecare Settings
• 12.3. Hospitals
• 12.4. Specialty Clinics

13. Pulmonary Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Pulmonary Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Pulmonary Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. GlaxoSmithKline plc
  • 16.3.2. AstraZeneca plc
  • 16.3.3. Boehringer Ingelheim International GmbH
  • 16.3.4. Novartis AG
  • 16.3.5. Sanofi S.A.
  • 16.3.6. Bayer Aktiengesellschaft
  • 16.3.7. Teva Pharmaceutical Industries Ltd.
  • 16.3.8. Vertex Pharmaceuticals Incorporated
  • 16.3.9. Johnson & Johnson
  • 16.3.10. Chiesi Farmaceutici S.p.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 311. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 312. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 313. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 314. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 315. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 316. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 317. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 318. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 319. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 320. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 321. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 322. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 323. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 324. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 325. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 326. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 327. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 328. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 329. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 330. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 331. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 332. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 333. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 334. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 20